Mar 14, 2016
A New View of Age-Related Macular Degeneration: Starving Eye Cells Contribute To Loss Of Vision In Seniors
Story guest authored by Derek Waldner with contributions by Dr. Mary Sunderland. Derek is a neuroscience graduate student at the University of Calgary and a knowledge translation intern at Fighting Blindness Canada.
Even though age-related macular degeneration (AMD) is the leading cause of blindness in people over the age of 50, we still don’t understand the cause of the disease. Thanks to Fighting Blindness Canada (FBC)-funded research, our understanding just took a giant leap forward! Groundbreaking research by Dr. Jean-Sébastien Joyal and collaborators across twelve institutions uncovered significant insights that pave the road to future therapies.
The vision loss that happens in AMD is caused by the abnormal growth of leaky blood vessels in the eye’s retina. It’s widely believed that this abnormal growth is triggered by oxygen deprivation. Amazingly, the research team discovered another cause: energy-starved photoreceptors.
“The inability of photoreceptors—nerve cells that capture light and generate vision—to produce energy may drive abnormal blood vessels to invade the retina,” said Dr. Joyal, an intensive care pediatrician at CHU Sainte-Justine and professor in the Department of Pediatrics at the University of Montreal. “We also discovered that photoreceptors do not rely exclusively on glucose to produce energy as previously thought, but also use lipids as a fuel substrate (like the heart, for example),” he said. These findings change the way we understand the cause of AMD, which opens the door to new treatments.
As individuals age, the function of some cellular processes—including processes associated with energy metabolism—is known to decline. In addition, photoreceptors consume a surprising amount of fuel. “They have the highest concentration of mitochondria—the “furnace” of the cell—and use more energy than any other cell in the body,” explained Dr. Lois Smith, who collaborated with Dr. Joyal on the study. Dr. Smith described how photoreceptors “have to be ‘on call’ all the time to signal light perception.” Because of this, photoreceptors have evolved a special system to ensure they get enough fuel. The research team demonstrated, for the first time, that photoreceptors need lipids, or fats, to function, and that they have special receptors and a special lipid sensor (FFAR1).
When the researcher team tricked photoreceptors into nutrient scarcity (by manipulating FFAR1), they discovered that more vascular endothelial growth factor (VEGF) was released. Increased VEGF leads to abnormal blood vessel growth, which causes vision loss in AMD. VEGF blockers already exist to treat AMD (such as Lucentis, Eylea and Avastin). The team’s important discovery enables the development of new drugs to act on FFAR1 before (or “upstream”) of VEGF. The hope is that this would result in an even more effective treatment for AMD. The team’s next steps will be to check if people have lipid sensors similar to the ones that were identified in the animal model. If so, existing inhibitors could be tried in clinical trials. FFAR inhibitors are already in clinical trials for diabetes.
We are proud that this FBC-funded discovery changes the way we think about the eye’s biology. This is why the research was published in the very prestigious journal Nature Medicine: the entire biomedical community needs to know about it! (It also happens to be Dr. Joyal’s second publication there in two years.) Thank you to all FBC donors for supporting Dr. Joyal as his team continues to expand our knowledge and open avenues to new sight-saving treatments.
About the Study:
The article “Retinal lipid and glucose metabolism dictates angiogenesis through lipid sensor Ffar1” was published in the journal Nature Medicine on March 14, 2016. Jean-Sébastien Joyal, MD, PhD is an intensive care pediatrician at CHU Sainte-Justine, researcher at the CHU Sainte-Justine Research Center, and professor in the Department of Pediatrics at the University of Montreal. He is first author of the study. His work was supported by the Burroughs Wellcome Fund Career Award for Medical Scientists; Fighting Blindness Canada; Canadian Institute of Health Research (CIHR); Fonds de Recherche du Québec—Santé (FRQS); Canadian Child Health Clinician Scientist Program; and CIHR New Investigator Award.
Co-Authors: Sun Y, Gantner ML, Shao Z, Evans L, Saba N, Fredrick T, Burnim S, Kim JS, Patel G, Juan AM, Hurst CG, Hatton CJ, Cui Z, Pierce KA, Bherer P, Aguilar E, Powner MB, Vevis K, Boisvert M, Fu Z, Levy E, Fruttiger M, Packard A, Rezende FA, Maranda B, Sapieha P*, Chen J, Friedlander M, Clish C and Smith L
Latest FBC News View All
A Message from the President and CEO For 45 years, the Foundation Fighting Blindness has raised and directed critical funding into sight-saving research for blinding eye diseases. From our earliest days as…Read More
In light of a recent article published by the Globe and Mail regarding the potential correlation between Avastin injections and increased glaucoma rates specifically in British Columbia, Fighting Blindness Canada is republishing…Read More
We are letting our community know about a patient experience study being conducted by Medicys Ltd., a medical research company that is looking for people with a confirmed diagnosis of Usher syndrome…Read More
On May 28, 2019, Dr. Chad Andrews, Senior Manager of Research and Education at Fighting Blindness Canada, will be taking part in Dispelling Myths Surrounding the Vision of Older People, an interdisciplinary…Read More
Join the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our eNews.